GLOW Blend Research Guide
A three-component research blend of GHK-Cu, BPC-157 and TB-500 (70 mg per vial). Summarizes the research on each component.
What is GLOW Blend?
GLOW is a three-component laboratory research blend. Per our product records, each vial contains GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, for 70 mg in total. See the product page for current specifications.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Maquart et al., 1988). BPC-157 is a synthetic 15-amino-acid peptide (Chang et al., 2011). TB-500 is the acetylated LKKTETQ fragment of thymosin beta-4 (Ho et al., 2012). Each component has its own guide.
Research areas studied
The findings below come from cell, animal and published clinical research. They describe what studies have examined and reported, not effects of any research material.
GHK-Cu research
In fibroblast cultures, GHK-Cu stimulated collagen synthesis at very low concentrations, independent of changes in cell number (Maquart et al., 1988). A 2015 review summarizes effects on collagen, glycosaminoglycan and decorin synthesis and on metalloproteinase activity, along with tissue repair findings in several animal models (Pickart et al., 2015). Most of this literature comes from cell culture and animal work.
BPC-157 research
In rat tendon explants and cultured tendon fibroblasts, BPC-157 increased fibroblast outgrowth, survival under oxidative stress and migration, and the effect was linked to the FAK-paxillin pathway (Chang et al., 2011). The evidence base is almost entirely preclinical.
TB-500 research
The LKKTETQ segment is described as the region of thymosin beta-4 responsible for actin binding and cell migration. Peer-reviewed work on the acetylated fragment itself is mainly analytical, such as a mass spectrometry method used in equine doping control (Ho et al., 2012).
What has not been studied
We found no peer-reviewed studies of this combination. Blend-specific findings cannot be inferred from component research alone, and interactions between the three components have not been studied in the sources reviewed.
Regulatory status
None of the components is an approved drug. FDA’s compounding safety page lists BPC-157, the thymosin beta-4 fragment and GHK-Cu for injectable routes among nominated substances whose nominations were withdrawn.
Storage and handling
Like most research blends, GLOW Blend is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.
When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.
Quality and COA
Every Zero Zero Collection product page has a View COA link. Certificates of analysis come from independent third-party testing by Freedom Diagnostics and are posted on our Quality page where available. A COA reports what the testing lab measured for one specific batch, so match the lot number on your vial to the certificate. Our FAQ explains how to read a COA.
GLOW Blend FAQ
What is in a GLOW 70mg vial?
Per our product records, GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, for 70 mg in total.
How is GLOW different from KLOW?
KLOW contains the same three components as GLOW plus KPV 10 mg, for 80 mg in total.
Has the GLOW combination been studied?
We found no peer-reviewed studies of this combination. The published research covers each component separately.
References
- Maquart FX, Pickart L, Laurent M, et al. (1988). FEBS Lett. PubMed 3169264
- Chang CH, Tsai WC, Lin MS, et al. (2011). J Appl Physiol. PubMed 21030672
- Ho EN, Kwok WH, Lau MY, et al. (2012). J Chromatogr A. PubMed 23084823
- Pickart L, Vasquez-Soltero JM, Margolina A (2015). Biomed Res Int. PubMed 26236730
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 28, 2026. fda.gov
For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.